Perrigo Q1 2026: Specialty Care growth masks persistent leverage

What happened

Perrigo's Q1 2026 results show market share gains in core categories and growth in the Specialty Care segment (Compeed, Opill, ellaOne) as part of the Three‑S plan to stabilize and streamline. However, the headline optimism masks that the company still operates under a heavy debt load (net debt/EBITDA ~7x) and thin interest coverage (~1.7x), leaving little margin for error. Management's cost‑saving programs (Supply Chain Reinvention, Project Energize) are on track, but the benefits are being offset by ongoing category headwinds and the drag from legacy liabilities, including the €1.64bn Irish tax dispute. While the stock trades at a deep discount to intrinsic value (~$13 vs. ~$24 DCF), the gap reflects market skepticism that the turnaround can deliver sustainable earnings and deleveraging. For now, the company is executing, but the path to a clean consumer health franchise remains long, and any misstep could quickly shift the narrative from recovery to distress.

Implication

Perrigo's Q1 2026 numbers reinforce the thesis that cost actions and brand momentum can partially offset category softness, but leverage remains the dominant risk. The three‑S plan is showing early signs of traction, but the company must demonstrate consistent cash‑flow generation to service its debt and eventually de‑lever. The unresolved Irish tax dispute and the risk of goodwill impairments remain wild cards that could impair equity value even if operations improve. For investors, the low valuation offers a margin of safety only if execution stays on track and the tax outcome is manageable; any negative development could lead to severe downside. We maintain a cautious‑but‑constructive stance, sizing positions appropriately and monitoring leverage and tax developments closely.

Thesis delta

The Q1 report does not materially alter the investment thesis; the core tension between operational progress and financial fragility remains unchanged. However, the continued momentum in Specialty Care brands offers a glimmer of hope that the "Strengthen" phase of the plan could eventually shift the company toward a more sustainable earnings profile, warranting a continued POTENTIAL BUY but with close attention to debt dynamics and tax resolution.